Sobi and Biogen's Elocta approved in Switzerland for hemophilia A

Swedish Orphan Biovitrum (STO: SOBI) has announced that it has received approval in Switzerland for the use of hemophilia A treatment Elocta (rFVIIIFc), which it is co-developing with US biotech major Biogen (Nasdaq: BIIB).

Elocta is now the only recombinant factor VIII Fc fusion protein with an extended half-life approved for hemophilia A treatment in Switzerland to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days.

Krassimir Mitchev, head of hemophilia at Sobi, said: “The Swiss approval of Elocta is an important milestone for the country’s hemophilia A community. Our focus is now to ensure timely and sustainable access to Elocta for people living with hemophilia A in Switzerland.”